New scan technique could sharpen cancer imaging

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all research participants: * Adults (age ≥ 18 years old) * Ability to understand and willingness to sign an informed consent form * Ability to adhere to the study visit schedule and other protocol requirements. * Willing and able to fast for at least 6 hours before and for the duration of the scan * No strenuous exercise for 24 hours prior to being scanned * Willing to lie on the scanner bed for up to 60 minutes For healthy volunteers only: • Free of history of cardiovascular, inflammatory, infections or metabolic diseases that would result in changes in bone marrow. For cancer patients only: * Patients with multiple myeloma who are planned to receive CAR T-cell therapy with any FDA-approved product, including Idecel and Ciltacel. Patients with prior chemo-immunotherapy are permitted. * Able to undergo bone marrow aspirate/biopsy procedure Exclusion Criteria: * Self-reported history of dysphoria or anxiety in closed spaces * Body weight \>240 kg due to limitations of the scanner bed * Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET/CT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy or bilateral ovarian removal is available) * Blood glucose greater than 200 as assessed by fingerstick method before injection of 18F-FDG * Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only. That is, PET scans are not performed as part of a patient's treatment plan (e.g. standard of care, therapeutic purposes, or clinical care) and the research study did not intend to provide therapeutic benefit to the patient. * Prisoners * Any condition that would prevent the understanding or rendering of informed consent. * Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.